Natera (NASDAQ:NTRA) Raised to Hold at StockNews.com

Natera (NASDAQ:NTRA) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Other research analysts have also issued reports about the stock. Leerink Partners raised their price target on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. UBS Group decreased their target price on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. BTIG Research boosted their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $125.69.

Natera Stock Performance

Shares of NTRA stock opened at $124.39 on Wednesday. The company has a market capitalization of $15.38 billion, a P/E ratio of -50.77 and a beta of 1.53. Natera has a 12-month low of $40.61 and a 12-month high of $133.54. The business’s 50 day moving average is $123.59 and its two-hundred day moving average is $113.06. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.97) EPS. Analysts expect that Natera will post -1.96 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 256 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the transaction, the insider now owns 111,891 shares of the company’s stock, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Natera news, insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 5,583 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the transaction, the chief executive officer now owns 200,710 shares of the company’s stock, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,164 shares of company stock valued at $6,157,291. 7.60% of the stock is currently owned by insiders.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the business. Covestor Ltd increased its position in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC raised its position in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC boosted its stake in shares of Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after buying an additional 135 shares during the period. Private Advisor Group LLC boosted its stake in shares of Natera by 5.2% in the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after buying an additional 135 shares during the period. Finally, Assetmark Inc. grew its position in shares of Natera by 2.1% during the third quarter. Assetmark Inc. now owns 7,353 shares of the medical research company’s stock worth $933,000 after buying an additional 150 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.